We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

By LabMedica International staff writers
Posted on 12 Apr 2021
Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. More...
The disorder causes a wide range of significant mental and physical disabilities, with profound behavioral changes and progressive impairment of social skills.

AD is a complex disorder influenced by environmental and genetic factors. Genome-wide association studies (GWAS) have identified several late-onset AD (LOAD)-associated risk loci proliferation in peripheral blood leukocytes including in T-lymphocytes, B-lymphocytes, polymorphonuclear leucocytes, monocytes, and macrophages have been reported.

A team of Medical Scientists mainly from the Oakland University-William Beaumont School of Medicine (Royal Oak, MI, USA) evaluated the utility of leucocyte epigenomic-biomarkers for Alzheimer’s Disease (AD) detection and elucidated its molecular pathogeneses. The team studied blood samples from two dozen Alzheimer's disease patients and the same number of cognitively health controls.

Approximately 500 ng of genomic DNA was extracted from each of the 48 samples, which subsequently were bisulfite converted using the EZ DNA Methylation-Direct Kit (Zymo Research, Orange, CA, USA). They performed genome-wide DNA methylation analysis of the blood samples using Infinium MethylationEPIC BeadChip array (Illumina, San Diego, CA, USA). Artificial Intelligence (AI) analysis was performed using a combination of CpG sites from different genes. They also used six artificial intelligences approaches to analyze their dataset, including support vector machine, random forest, and deep learning. Deep learning is a branch of machine learning that aims to mimic the neural networks of animal brains.

The team reported that each of the AI approaches could predict Alzheimer's disease with high accuracy, yielding areas under the curve (AUC) of at least 0.93. Deep learning further improved upon that with an AUC of 0.99 and a sensitivity and specificity of 97% using intragenic markers. Similar results could be reached with intergenic markers, as well. The group noted that the addition of conventional clinical predictors or mental state analyses did not further improve performance. The analysis highlighted a number of genes and pathways known to be disrupted in Alzheimer's disease. Epigenetically altered genes included, for instance, CR1L and CTSV, which are involved in the morphology of the cerebral cortex, as well as S1PR1 and LTB4R, which are involved in inflammatory response.

Ray O. Bahado-Singh, MD, a Professor of Obstetrics and Gynecology and lead author of the study, said, “We found that the genetic analysis accurately predicted the absence or presence of Alzheimer's, allowing us to read what is going on in the brain through the blood. The results also gave us a readout of the abnormalities that are causing Alzheimer's disease. This has future promise for developing targeted treatment to interrupt the disease process.” The study was published on March 31, 2021 in the journal PLOS ONE.

Related Links:
Oakland University-William Beaumont School of Medicine
Zymo Research
Illumina



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
New
Pipette
Accumax Smart Series
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.